Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Combined With Toripalimab and HAIC for Intrahepatic Cholangiocarcinoma
NCT06313554Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Open-label, single-arm trial of surufatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06313554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313554.